|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | Siemens AG (NYSE:SI), a large diversified manufacturer with substantial healthcare interests. |
|---|---|
| Transferring Party | Dade Behring Holdings, Inc. (NASDAQ:DADE), a maker of clinical diagnostic instruments, reagents, and consumable supplies and services, addressing clinical laboratories worldwide. |
| Sector | Diagnostics |
| Date | November 6, 2007 |
| Analysis Combined company will become one of the largest providers of clinical diagnostic products and services in the world. Dade represents one of the last large general lab diagnostic companies. Siemens has about 12% market share; Dade and rival Beckman each have about 11-12%; and Roche has about 18%. Diagnostic market is growing at 6-7% annually. Reflecting other activity in the diagnostics sector, after terminating its $8.1b deal for Abbott, GE said it would continue to seek acquisitions there. Deal value -- $7b, on sales of $1.78b (3.9x) and EBITDA of $407.4m (17.2x). Recently, Siemens also made a $1.86b acquisition of Diagnostic Products Corp and a $5.4b puchase of Bayer Diagnostics. | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |